[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100619320":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":14,"responsibleParty":37,"collaborators":7,"id":39,"slug":7,"hasResults":40,"nctId":41,"briefTitle":42,"officialTitle":42,"acronym":43,"eligibilityCriteria":44,"healthyVolunteers":40,"sex":45,"minAge":46,"maxAge":7,"enrollmentInfo":47,"targetDuration":7,"studyType":50,"phases":7,"briefSummary":51,"conditions":52,"keywords":54,"overallStatus":17,"whyStopped":7,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},{"fullName":5,"class":6},"University Hospital, Strasbourg, France","OTHER",null,[9],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"Pierre BOYER, MD","CONTACT","33 3 69 55 14 69","pierre.boyer@chru-strasbourg.fr",[15],{"facility":16,"status":17,"city":18,"state":7,"zip":19,"country":20,"cosmosGeoPoint":21,"geoPoint":26,"contacts":27},"Laboratoire de Bactériologie - CHU de Strasbourg - France","RECRUITING","Strasbourg","67091","France",{"type":22,"coordinates":23},"Point",[24,25],7.74553,48.58392,{"lat":25,"lon":24},[28,29,33,35],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},{"name":30,"role":11,"phone":31,"phoneExt":7,"email":32},"Émilie TALAGRAND-REBOUL, MD","33 3 69 55 14 57","Emilie.TALAGRANDREBOUL@chru-strasbourg.fr",{"name":10,"role":34,"phone":7,"phoneExt":7,"email":7},"PRINCIPAL_INVESTIGATOR",{"name":36,"role":34,"phone":7,"phoneExt":7,"email":7},"Émilie TALAGRAND-REBOUL",{"type":38,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100619320",false,"NCT07343089","A Multicenter Real-life Study of Disseminated Borreliosis Cases Occurring in Patients Receiving Anti-CD20 Treatment in France","BorDiMab","Inclusion Criteria:\n\n* Minor or adult subject\n* Having presented disseminated borreliosis confirmed by molecular biology (Borrelia burgdorferi sl. or Borrelia miyamotoi) within 24 months of receiving treatment with an anti-CD20 monoclonal antibody between January 1, 2010, and July 30, 2025.\n\nExclusion Criteria:\n\n\\- Refusal to participate in the study","ALL","1 Year",{"count":48,"type":49},100,"ESTIMATED","OBSERVATIONAL","Clinical, biological, radiological, and pharmacological description of cases of disseminated borreliosis (Borrelia burgdorferi sl. and Borrelia miyamotoi) occurring in patients who received drug treatment based on anti-CD20 monoclonal antibodies.",[53],"Borrelia Infections",[55,53,56,57,58],"Borreliosis, Lyme","Borrelia Burgdorferi","Borrelia Miyamotoi","Anti-CD20 monoclonal antibodies","2026-01-06",{"date":61,"type":62},"2026-01-15","ACTUAL",{"date":64,"type":62},"2025-08-29",{"date":66,"type":49},"2026-08-29",{"name":5,"class":6},1]